


THERAPIES

TO STANDARD OF CARE?

FROM BREAKTHROUGH INNOVATION

CAR-T CELL



CAR-T Cell Therapies: A new hope for cancer treatment

CAR-T cell therapies are in the spotlight for their:



Targeted action: Specifically destroying cancer cells



Personalized approach: Leveraging the patient's own T cells



Breakthrough results: Offering hope for sustained remission in resistant cancers




Current indications approved for CAR-T cell therapies in EU and the US

Indications	Therapy lines			Product with
	1 st line	2 nd line	3 rd line	earliest therapy line
<u>Pediatric</u> acute lymphoblastic leukemia (ALL)			$ \Longrightarrow $	KYMRIAH
<u>Adult</u> acute lymphoblastic leukemia (ALL)				TECARTUS
Diffuse large B-cell lymphoma (DLBCL)				
High Grade B-cell lymphoma (HGBCL)				
Primary mediastinal large B-cell lymphoma (PMBCL)				Breyanzi
Follicular lymphoma (FL)		Grade 3B	All others	Breyanzi
Mantle cell lymphoma (MCL)			\rightarrow	TECARTUS
Multiple myeloma (MM)				CARVYKTI

Sources: European Medicines Agency, U.S. Food and Drug Administration

Advention

Drivers that will shape the future of the CAR-T cell therapy ecosystem



Advention

Learn more by requesting a copy of our white paper today!

Or contact us:

frederic.misse@adventionbp.com gonzague.godinot@adventionbp.com steven.ries@adventionbp.com

Advention